Loss of extracellular superoxide dismutase induces severe IL-23-mediated skin inflammation in mice

Journal of Investigative Dermatology

Volumn 133, Issue 3, 2013, Pages 732-741

  Lee, Yun Sang ^a   Cheon, In Su ^a   Kim, Byung Hak ^a   Kwon, Myung Ja ^a   Lee, Han Woong ^a   Kim, Tae Yoon ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; INTERLEUKIN 23; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DENDRITIC CELL; DERMATITIS; DISEASE SEVERITY; IMMUNE RESPONSE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; TRANSGENIC MOUSE;

EID: 84873736060     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.406     Document Type: Article

References (42)

1. Adachi T, Toishi T, Takashima E et al. (2006) Infliximab neutralizes the suppressive effect of TNF-alpha on expression of extracellular-superoxide dismutase in vitro. Biol Pharm Bull 29: 2095-8
2. Afonso V, Champy R, Mitrovic D et al. (2007) Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine 74: 324-9
3. Amadi-Obi A, Yu CR, Liu X et al. (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13: 711-8
4. Belkaid Y, Hoffmann KF, Mendez S et al. (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497-506
5. Bettelli E, Carrier Y, Gao W et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-8
6. Blauvelt A (2007) New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-beta1. Expert Rev Dermatol 2: 1-10
7. Carlsson LM, Jonsson J, Edlund T et al. (1995) Mice lacking extracellular superoxide dismutase are more sensitive to hyperoxia. Proc Natl Acad Sci USA 92: 6264-8
8. Cesare AD, Meglio PD, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129: 1339-50
9. Chen Z, Laurence A, O'shea JJ (2007) Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 19: 400-8
10. Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129: 1339-50
11. Fattman CL, Schaefer LM, Oury TD (2003) Extracellular speroxide dismutase in biology and medicine. Free Radic Biol Med 35: 236-56
12. Flisiak I, Chodynicka B, Porebski P et al. (2002) Association between psoriasis severity and transforming growth factor beta1 and beta2 in plasma and scales from psoriatic lesions. Cytokine 19: 121-5
13. Gao F, Koenitzer JR, Tobolewski JM et al. (2008) Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan. J Biol Chem 283: 6058-66
14. Gillitzer R, Ritter U, Spandau U et al. (1996) Differential expression of GRO-a and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 107: 778-82
15. Hedrick MN, Lonsdorf AS, Shirakawa AK et al. (2009) CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 119: 2317-29
16. Hjalmarsson K, Marklund SL, Engstrom A et al. (1987) Isolation and sequence of complementary DNA encoding human extracellular superoxide dismutase. Proc Natl Acad Sci USA 84: 6340-4
17. Ivanov II, McKenzie BS, Zhou L et al. (2006) The orphan nuclear receptor RORgamma-t directs the differentiation program of proinflammatory IL-17\+ T cells. Cell 126: 1121-33
18. Kim Y, Kim BH, Lee H et al. (2011) Regulation of skin inflammation and angiogenesis by EC-SOD via HIF-1a and NF-kB pathways. Free Radic Biol Med 51: 1985-95
19. Krueger G, Callis K (2004) Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol 140: 218-25
20. Laurila JP, Laatikainen LE, Castellone MD et al. (2009) SOD3 reduces inflammatory cell migration by regulating adhesion molecule and cytokine expression. PLoS One 4: e5786
21. Lee E, Trepicchio L, Oestreicher L et al. (2004) Increased expression of interleukin 23p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199: 125-30
22. Lee YS, Ahjoku A-O, Yu C-R et al. (2011) Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. Immunology 132: 492-502
23. Lillis JV, Guo CS, Lee JJ et al. (2010) Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis. Arch Dermatol 146: 918-9
24. Liu X, Lee YS, Yu CR et al. (2008) Loss of STAT3 in CD4\+ T cells prevents development of experimental autoimmune diseases. J Immunol 180: 6070-6
25. Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445: 866-73
26. Mangan PR, Harrington LE, O'Quinn DB et al. (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231-4
27. Marklund SL (1982) Human copper-containing superoxide dismutase of high molecular weight. Proc Natl Acad Sci USA 79: 7634-8
28. Nickoloff BJ, Xin H, Nestle FO et al. (2007) The cytokine and chemokine network in psoriasis. Clin In Dermatol 25: 568-73
29. Nurieva R, Yang XO, Martinez G et al. (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448: 480-3
30. Petersen SV, Oury T, Oestergaard L et al. (2004) Extracellular superoxide dismutase (EC-SOD) binds to type I collagen and protects against oxidative fragmentation. J Biol Chem 279: 13705-10
31. Piskin G, Sylva-Steenland RM, Bos JD et al. (2006) In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 176: 1908-15
32. Rizzo HL, Kagami S, Phillips KG et al. (2011) IL-23-mediated psoriasislike epidermal hyperplasisa is dependent on IL-17A. J Immunol 186: 1495-502
33. Rottman JB, Smith TL, Ganley KG et al. (2001) Potential role of the chemokine receptors CXCR3, CCR4, and the integrin aEb7 in the pathogenesis of psoriasis vulgaris. Lab Invest 81: 355-47
34. Sandstrom J, Carlsson L, Marklund SL et al. (1992) The heparin-binding domain of extracellular superoxide dismutase C and formation of variants with reduced heparin affinity. J Biol Chem 267: 18205-9
35. Sano S, Chan KS, Carbajal S et al. (2005) Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11: 43-9
36. Sano S, Chan KS, DiGiovanni J (2008) Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. J Dermatol Sci 50: 1-14
37. Schon MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352: 1899-912
38. Stenlund P, Andersson D, Tibell LA (1997) Subunit interacation in extracellular superoxide dismutase: effects of mutations in the N-terminal domain. Protein Sci 6: 2350-8
39. Stockinger B, Veldhoen M (2007) Differentiation and function of Th17 T cells. Curr Opin Immunol 19: 281-6
40. Stralin P, Marklund SL (2000) Multiple cytokines regulate the expression of extracellular superoxide dismutase in human vascular smooth muscle cells. Atherosclerosis 151: 433-41
41. Tonel G, Conrad C, Laggner U et al. (2010) Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol 185: 5688-91
42. Zheng Y, Danilenko DM, Valdez P et al. (2007) T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acantosis. Nature 445: 648-51